ArticleArchives of osteoporosis2026
Osteoporosis risk in alpha and beta thalassemia: An age- and sex-specific retrospective cohort study.
Article in Archives of osteoporosis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleDifferential skeletal risks between alpha- and beta-thalassemia subtypes remain unclear. MAIN
resultBeta-thalassemia correlates with higher fracture risk than alpha-thalassemia. Notably, males aged 18-50 with beta-thalassemia show a 14-fold increase in osteoporosis. SIGNIFICANCE: Identifies a notably elevated osteoporosis risk in young males, supporting consideration of earlier skeletal surveillance. PURPOSE: The differences in osteoporosis and fracture risk between alpha- and beta-thalassemia subtypes, and how these differences vary by age and sex, remain poorly understood. We conducted a large-scale analysis to characterize these risks and guide risk-stratified protocols.
methodsThis retrospective cohort study used the TriNetX health research network. Patients with alpha- and beta-thalassemia (identified by ICD-10 codes) were matched 1:1 with non-anemic controls by age, sex, race, and comorbidities (chronic kidney disease, diabetes mellitus, rheumatoid arthritis, malnutrition, and endocrine dysfunction) using propensity scores. We assessed the risk of osteoporosis, fractures, and mortality from Kaplan-Meier analyses.
resultsBeta-thalassemia patients have a significantly greater risk of osteoporosis (HR = 1.26, 95% CI: 1.11-1.43) than alpha-thalassemia patients. Within the beta-thalassemia group, males demonstrated a risk of osteoporosis that was more than three times higher than that of controls (HR = 3.28, 95% CI: 2.51-4.28), which was notably higher than that observed in females (HR = 1.42, 95% CI: 1.26-1.60). Young males (aged 18-50) demonstrated a markedly elevated risk of osteoporosis (HR = 13.97, 95% CI: 7.30-26.73) and mortality (HR = 6.31, 95% CI: 3.62-11.01) compared to matched controls.
conclusionBeta-thalassemia is associated with worse skeletal outcomes than alpha-thalassemia. Young male patients demonstrate substantially elevated risk of osteoporosis and mortality. These findings highlight the need for age- and sex-specific risk assessment in thalassemia patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.